Verrica Pharmaceuticals (NASDAQ:VRCA – Free Report) had its price target decreased by TD Cowen from $15.00 to $10.00 in a research report released on Monday, Benzinga reports. TD Cowen currently has a buy rating on the stock.
Several other brokerages also recently weighed in on VRCA. Brookline Capital Management restated a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, October 2nd. Royal Bank of Canada lowered their target price on Verrica Pharmaceuticals from $13.00 to $11.00 and set an “outperform” rating for the company in a research note on Friday, October 4th. Finally, Needham & Company LLC restated a “hold” rating and set a $12.00 target price on shares of Verrica Pharmaceuticals in a research note on Thursday, October 3rd. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $11.40.
Check Out Our Latest Stock Analysis on Verrica Pharmaceuticals
Verrica Pharmaceuticals Trading Down 0.7 %
Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.06. The company had revenue of $5.18 million during the quarter, compared to the consensus estimate of $4.70 million. Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%. Research analysts predict that Verrica Pharmaceuticals will post -1.58 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Verrica Pharmaceuticals
A number of hedge funds have recently bought and sold shares of the company. Quest Partners LLC bought a new stake in shares of Verrica Pharmaceuticals during the second quarter valued at approximately $50,000. Key Financial Inc bought a new stake in shares of Verrica Pharmaceuticals during the second quarter valued at approximately $69,000. Rhumbline Advisers raised its holdings in shares of Verrica Pharmaceuticals by 20.4% during the second quarter. Rhumbline Advisers now owns 26,591 shares of the company’s stock valued at $194,000 after buying an additional 4,514 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Verrica Pharmaceuticals during the second quarter valued at approximately $332,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Verrica Pharmaceuticals by 8.1% during the second quarter. Bank of New York Mellon Corp now owns 58,680 shares of the company’s stock valued at $428,000 after buying an additional 4,393 shares during the last quarter. 42.45% of the stock is currently owned by institutional investors and hedge funds.
Verrica Pharmaceuticals Company Profile
Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.
Recommended Stories
- Five stocks we like better than Verrica Pharmaceuticals
- Consumer Discretionary Stocks Explained
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Overbought Stocks Explained: Should You Trade Them?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Compound Interest and Why It Matters When Investing
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.